Cerebral Folate Deficiency ¹ (CFD) is a neurological condition characterised by low levels of 5-methyltetrahydrofolate (5-MTHF) in the cerebrospinal fluid, despite normal or elevated levels of folate in the blood. This deficiency can impair brain development and function, particularly in young children, leading to symptoms such as developmental delay, seizures, and speech and language difficulties. While the main treatment is folate supplementation to restore folate levels in the brain,² many patients require additional support to manage the wide range of symptoms.

Adjunctive therapies, including anticonvulsant medications and nutritional support, can play a crucial role in improving clinical outcomes and enhancing quality of life. These therapies do not replace folate supplementation but are often necessary to address complications such as epilepsy, behavioural challenges and feeding difficulties. 

Anticonvulsant therapy

Seizures are a common feature in individuals with CFD. These can range from mild to severe and may appear early in life, sometimes even before a formal diagnosis is made. While folate treatment can help reduce the frequency of seizures in some patients, many still require additional medical management to control seizures.

Several anticonvulsant medications are used to treat seizures in CFD, depending on the patient’s age, seizure type and overall health. Commonly prescribed medications include Levetiracetam, Lamotrigine and Valproic acid.

Some anticonvulsants, such as valproate, carbamazepine and phenytoin, can interfere with folate metabolism, potentially worsening CFD or reducing the effectiveness of folinic acid therapy. For this reason, the choice of anticonvulsant must be carefully considered. Regular monitoring is essential to assess both seizure control and folate levels.

To prevent interactions that could impair treatment, neurologists often work closely with metabolic specialists to adjust folinic acid doses when anticonvulsants are used. The goal is to strike a balance between controlling seizures and maintaining adequate folate levels in the brain.

Anticonvulsant therapy, when carefully selected and monitored, is an essential part of comprehensive management in many cases of CFD.

Behavioural Therapies

Many individuals with Cerebral Folate Deficiency experience behavioural and developmental challenges. These may include autistic features,³ irritability, attention difficulties and delays in speech and language. Such symptoms can persist even with folate supplementation, making behavioural interventions a vital component of care.

Applied Behaviour Analysis (ABA) is a structured, evidence-based therapy often used to support children with autism spectrum disorders and related conditions. In CFD, ABA can help improve communication skills, social interaction and adaptive behaviours for daily living. Therapy is usually personalised, involving one-to-one sessions that target specific goals based on the child’s needs.

Speech therapy focuses on enhancing language skills, improving articulation, and supporting alternative communication methods if needed. Occupational therapy works on fine motor skills, sensory integration, and daily functional abilities, such as dressing and feeding.

Research and clinical observations suggest that behavioural therapies are most effective when started early and in combination with medical treatment. Improvements may be gradual but can significantly enhance independence, social engagement and overall quality of life.

Behavioural interventions complement folinic acid therapy by addressing the developmental and psychosocial aspects of CFD, ensuring that treatment is not only biochemical but also functional.

Nutritional support

Nutrition plays a key role in supporting brain function and overall health in individuals with Cerebral Folate Deficiency. While folinic acid supplementation addresses the primary deficiency, maintaining a balanced diet helps sustain neurological health, reduce secondary deficiencies and support growth and development.

In addition, including natural sources of folate in the diet can complement medical treatment. Examples of this include: leafy green vegetables (spinach, kale), citrus fruits (oranges, grapefruits), legumes (lentils, chickpeas) and fortified grains and cereals. Although dietary folate cannot replace folate therapy in CFD, it can help optimise nutrient availability.

Some individuals with CFD, particularly children, may experience feeding difficulties such as poor appetite, sensory aversions, or difficulty chewing and swallowing. These challenges can be managed through feeding therapy with a speech or occupational therapist, modified food textures and structured mealtime routines to encourage intake.

Beyond folate, other nutrients such as vitamin B12, iron and omega-3 fatty acids are also important for cognitive and neurological health. Regular blood tests can help identify deficiencies, allowing dietitians to recommend appropriate supplements.

Nutritional support, when tailored to individual needs, helps reinforce the biochemical treatment of CFD and contributes to better long-term outcomes.

Integrated care approach

CFD y is a complex condition that affects neurological, developmental and nutritional health. Managing it effectively often requires collaboration between neurologists, metabolic specialists, dietitians and speech, occupational, and behavioural therapists.

Individuals with CFD experience a range of different symptoms, so personalising treatments ensures the medical management addresses the specific type and severity of seizures. It also ensures that behavioural interventions target the most relevant developmental needs and nutritional strategies accommodate feeding abilities and dietary preferences.

Regular follow-up appointments allow for the review of seizure control as well as adjusting anticonvulsant or folate doses. It also allows specialists to track developmental progress and adapt therapy goals. 

When medical, behavioural and nutritional strategies are coordinated, patients are more likely to experience better symptom control, improved cognitive and social development and enhanced quality of life for both patients and families.

An integrated care model ensures that treatment is comprehensive, adaptable and focused on both immediate symptom relief and long-term functional outcomes.

Conclusion

Cerebral Folate Deficiency is a condition that requires more than folinic acid supplementation alone. While restoring folate levels in the brain is the cornerstone of treatment, many individuals benefit greatly from adjunctive therapies that target specific complications and support overall development.

Anticonvulsants, behavioural therapies and nutritional support ensure optimal brain health and growth. When these interventions are combined within an integrated care framework, they can significantly improve quality of life, maximise developmental potential and reduce the long-term impact of the disorder.

Ongoing research and clinical collaboration remain essential to refining these approaches, ensuring that every individual with CFD receives tailored, effective and holistic care.

Summary 

• Adjunctive therapies play a crucial role in optimising outcomes in CFD
• Combined approach leads to better symptom control and developmental progress
• Ongoing research is needed to refine and personalise adjunctive strategies